Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): Examining whether different variables govern different time segments of survival

Annals of Hematology

Volumn 90, Issue 4, 2011, Pages 423-428

  Barlogie, Bart ^a   Bolejack, Vanessa ^b   Schell, Michael ^c   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

IFM trials; Myeloma; SWOG 9321; Total therapy trials; Transplant trials

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BONE LESION; CALCIUM BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CREATININE BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT; BLOOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT OUTCOME;

BETA 2-MICROGLOBULIN; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955936633     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1130-y     Document Type: Article

References (20)

1. van Rhee F, Anaissie E, Angtuaco E et al (2010) Chapter 109. Myeloma. In: Kaushansky K (ed) Williams hematology, 8th edn. McGraw-Hill, New York (in press)
2. Kyle R, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860-1873
3. Greipp PR, San Miguel J, Durie BGM et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:1-9
4. Durie BGM, Salmon SE (1975) A clinical system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842-854
5. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502 (Pubitemid 38010075)
6. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883 (Pubitemid 36532313)
7. Cavo M, Tosi P, Zamagni E et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. JCO 25:2434-2441 (Pubitemid 46999214)
8. Barlogie B, Tricot G, Rasmussen E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple. N Engl J Med 354:1021-1030
9. Nair B, van Rhee F, Shaughnessy JD et al (2010) Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined lowrisk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood 115:4168-4173. doi:10.1182/blood-2009-11- 255620
10. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
11. Richardson PG, Blood E, Mitsiades C et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464
12. Palumbo A, Bringhen S, Liberati A et al (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112:3107-3114
13. Rajkumar SV, Jacobus S, Callander N et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 11:29-37
14. San Miguel JF, Schlag R, Khuagena NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 356:906-917
15. Barlogie B, Kyle RA, Anderson KC et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. JCO 24:929-936 (Pubitemid 46638847)
16. Barlogie B, Attal M, Crowley J et al (2010) Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group and University of Arkansas for Medical Sciences. JCO 28:1209-1214
17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
18. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-202
19. Han G, Schell MJ, Kim J (2010) Improved survival modeling using a reduced piecewise exponential approach. J Am Stat Assoc (in press)
20. Mueller HG, Wang JL (1994) Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics 50:61-76